Cameron W Brennan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9127397/publications.pdf

Version: 2024-02-01

6592 6979 60,081 157 79 154 citations h-index g-index papers 159 159 159 63053 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature, 2008, 455, 1061-1068.	13.7	6,879
2	Integrated genomic analyses of ovarian carcinoma. Nature, 2011, 474, 609-615.	13.7	6,541
3	Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell, 2010, 17, 98-110.	7.7	6,138
4	The Somatic Genomic Landscape of Glioblastoma. Cell, 2013, 155, 462-477.	13.5	3,979
5	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nature Genetics, 2019, 51, 202-206.	9.4	2,702
6	Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. New England Journal of Medicine, 2015, 372, 2481-2498.	13.9	2,582
7	Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes and Development, 2007, 21, 2683-2710.	2.7	1,952
8	CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nature Medicine, 2013, 19, 1264-1272.	15.2	1,812
9	<i>MET</i> amplification occurs with or without <i>T790M</i> mutations in <i>EGFR</i> mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 20932-20937.	3.3	1,557
10	Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell, 2004, 6, 17-32.	7.7	1,161
11	Glioblastoma stem-like cells give rise to tumour endothelium. Nature, 2010, 468, 829-833.	13.7	1,091
12	A brain tumor molecular imaging strategy using a new triple-modality MRI-photoacoustic-Raman nanoparticle. Nature Medicine, 2012, 18, 829-834.	15.2	1,029
13	An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells. Science, 2013, 340, 626-630.	6.0	1,014
14	Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies. Science, 2007, 318, 287-290.	6.0	849
15	PTEN/PI3K/Akt Pathway Regulates the Side Population Phenotype and ABCG2 Activity in Glioma Tumor Stem-like Cells. Cell Stem Cell, 2009, 4, 226-235.	5.2	740
16	Genomic Analysis of Non- <i>NF2</i> Meningiomas Reveals Mutations in <i>TRAF7</i> , <i>KLF4</i> , <i>AKT1</i> , and <i>SMO</i> . Science, 2013, 339, 1077-1080.	6.0	714
17	Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nature Genetics, 2012, 44, 1179-1181.	9.4	692
18	p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature, 2008, 455, 1129-1133.	13.7	658

#	Article	IF	CITATIONS
19	Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells. Cell, 2020, 181, 1643-1660.e17.	13.5	554
20	Both p16Ink4a and the p19Arf-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 5947-5952.	3 . 3	537
21	Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nature Genetics, 2014, 46, 451-456.	9.4	525
22	Perivascular Nitric Oxide Activates Notch Signaling and Promotes Stem-like Character in PDGF-Induced Glioma Cells. Cell Stem Cell, 2010, 6, 141-152.	5.2	493
23	Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. Nature Reviews Cancer, 2014, 14, 92-107.	12.8	469
24	The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes and Development, 2009, 23, 1327-1337.	2.7	465
25	Emerging insights into the molecular and cellular basis of glioblastoma. Genes and Development, 2012, 26, 756-784.	2.7	463
26	Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 3041-3046.	3.3	459
27	Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes and Development, 2010, 24, 1731-1745.	2.7	454
28	Glioblastoma Subclasses Can Be Defined by Activity among Signal Transduction Pathways and Associated Genomic Alterations. PLoS ONE, 2009, 4, e7752.	1.1	450
29	Macrophage Ontogeny Underlies Differences in Tumor-Specific Education in Brain Malignancies. Cell Reports, 2016, 17, 2445-2459.	2.9	450
30	Saccade preparation inhibits reorienting to recently attended locations Journal of Experimental Psychology: Human Perception and Performance, 1989, 15, 673-685.	0.7	446
31	High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell, 2006, 9, 313-325.	7.7	404
32	Comparative Oncogenomics Identifies NEDD9 as a Melanoma Metastasis Gene. Cell, 2006, 125, 1269-1281.	13.5	380
33	Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid. Nature, 2019, 565, 654-658.	13.7	361
34	High-resolution genomic profiles of human lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 9625-9630.	3.3	360
35	Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature, 2007, 447, 966-971.	13.7	355
36	Reprogramming of a melanoma genome by nuclear transplantation. Genes and Development, 2004, 18, 1875-1885.	2.7	321

#	Article	IF	Citations
37	Differential Sensitivity of Glioma- versus Lung Cancer–Specific EGFR Mutations to EGFR Kinase Inhibitors. Cancer Discovery, 2012, 2, 458-471.	7.7	304
38	Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. Cancer Discovery, 2017, 7, 1018-1029.	7.7	302
39	Passenger deletions generate therapeutic vulnerabilities in cancer. Nature, 2012, 488, 337-342.	13.7	294
40	Extrageniculate vision in hemianopic humans: saccade inhibition by signals in the blind field. Science, 1990, 250, 118-121.	6.0	276
41	Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo. Science Translational Medicine, 2015, 7, 274ra17.	5.8	257
42	High-resolution characterization of the pancreatic adenocarcinoma genome. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 9067-9072.	3.3	246
43	The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 9435-9440.	3.3	246
44	Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML. Cancer Cell, 2017, 32, 506-519.e5.	7.7	240
45	PLAGL2 Regulates Wnt Signaling to Impede Differentiation in Neural Stem Cells and Gliomas. Cancer Cell, 2010, 17, 497-509.	7.7	224
46	Long-term risk of radionecrosis and imaging changes after stereotactic radiosurgery for brain metastases. Journal of Neuro-Oncology, 2015, 125, 149-156.	1.4	224
47	A Phase 2 Trial of Stereotactic Radiosurgery Boost After Surgical Resection for Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2014, 88, 130-136.	0.4	218
48	Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine. Oncotarget, 2013, 4, 1729-1736.	0.8	213
49	Loss of ATM/Chk2/p53 Pathway Components Accelerates Tumor Development and Contributes toÂRadiation Resistance in Gliomas. Cancer Cell, 2010, 18, 619-629.	7.7	211
50	An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. Oncogene, 2009, 28, 2773-2783.	2.6	205
51	Molecular subclassification of diffuse gliomas: Seeing order in the chaos. Glia, 2011, 59, 1190-1199.	2.5	201
52	Molecular diversity of astrocytes with implications for neurological disorders. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 8384-8389.	3.3	193
53	Marked Genomic Differences Characterize Primary and Secondary Glioblastoma Subtypes and Identify Two Distinct Molecular and Clinical Secondary Glioblastoma Entities. Cancer Research, 2006, 66, 11502-11513.	0.4	187
54	Tumor-Infiltrating Lymphocytes in Glioblastoma Are Associated with Specific Genomic Alterations and Related to Transcriptional Class. Clinical Cancer Research, 2013, 19, 4951-4960.	3.2	182

#	Article	IF	CITATIONS
55	<i>PDGFRA</i> gene rearrangements are frequent genetic events in <i>PDGFRA</i> amplified glioblastomas. Genes and Development, 2010, 24, 2205-2218.	2.7	181
56	Metabolic Imaging of the Human Brain with Hyperpolarized 13C Pyruvate Demonstrates 13C Lactate Production in Brain Tumor Patients. Cancer Research, 2018, 78, 3755-3760.	0.4	179
57	Integrative Genome Comparison of Primary and Metastatic Melanomas. PLoS ONE, 2010, 5, e10770.	1.1	166
58	The role of radiotherapy following gross-total resection of atypical meningiomas. Journal of Neurosurgery, 2012, 117, 679-686.	0.9	160
59	Combined cDNA Array Comparative Genomic Hybridization and Serial Analysis of Gene Expression Analysis of Breast Tumor Progression. Cancer Research, 2006, 66, 4065-4078.	0.4	159
60	Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE. Clinical Cancer Research, 2018, 24, 737-743.	3.2	154
61	Emerging Therapies for Glioblastoma. JAMA Neurology, 2014, 71, 1437.	4.5	148
62	Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence. Nature Genetics, 2018, 50, 62-72.	9.4	137
63	Splicing factor hnRNPH drives an oncogenic splicing switch in gliomas. EMBO Journal, 2011, 30, 4084-4097.	3.5	134
64	High-Resolution Global Profiling of Genomic Alterations with Long Oligonucleotide Microarray. Cancer Research, 2004, 64, 4744-4748.	0.4	133
65	Proteasomal and Genetic Inactivation of the NF1 Tumor Suppressor in Gliomagenesis. Cancer Cell, 2009, 16, 44-54.	7.7	132
66	18F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers. Cancer Research, 2011, 71, 5164-5174.	0.4	113
67	A Genome-Wide Screen Reveals Functional Gene Clusters in the Cancer Genome and Identifies EphA2 as a Mitogen in Glioblastoma. Cancer Research, 2006, 66, 10815-10823.	0.4	110
68	Feedback Circuit among INK4 Tumor Suppressors Constrains Human Glioblastoma Development. Cancer Cell, 2008, 13, 355-364.	7.7	109
69	Pten and p53 Converge on c-Myc to Control Differentiation, Self-renewal, and Transformation of Normal and Neoplastic Stem Cells in Glioblastoma. Cold Spring Harbor Symposia on Quantitative Biology, 2008, 73, 427-437.	2.0	109
70	Mig-6 controls EGFR trafficking and suppresses gliomagenesis. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 6912-6917.	3.3	109
71	Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas. Clinical Cancer Research, 2019, 25, 5537-5547.	3.2	107
72	Identification of DOK genes as lung tumor suppressors. Nature Genetics, 2010, 42, 216-223.	9.4	105

#	Article	IF	CITATIONS
73	Nuclear cloning of embryonal carcinoma cells. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 13985-90.	3.3	104
74	Concordance between Functional Magnetic Resonance Imaging and Intraoperative Language Mapping. Stereotactic and Functional Neurosurgery, 1999, 72, 95-102.	0.8	99
75	The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 6459-6464.	3.3	99
76	microRNA Regulatory Network Inference Identifies miR-34a as a Novel Regulator of TGF- \hat{l}^2 Signaling in Glioblastoma. Cancer Discovery, 2012, 2, 736-749.	7.7	99
77	Double Minute Chromosomes in Glioblastoma Multiforme Are Revealed by Precise Reconstruction of Oncogenic Amplicons. Cancer Research, 2013, 73, 6036-6045.	0.4	94
78	Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 19024-19029.	3.3	91
79	Phase II Study of Bevacizumab, Temozolomide, and Hypofractionated Stereotactic Radiotherapy for Newly Diagnosed Glioblastoma. Clinical Cancer Research, 2014, 20, 5023-5031.	3.2	89
80	Assessment of the Language Laterality Index in Patients with Brain Tumor Using Functional MR Imaging: Effects of Thresholding, Task Selection, and Prior Surgery. American Journal of Neuroradiology, 2008, 29, 528-535.	1.2	81
81	Neurosurgery for Brain Tumors: Update on Recent Technical Advances. Current Neurology and Neuroscience Reports, 2011, 11, 313-319.	2.0	81
82	Loss of the tyrosine phosphatase PTPRD leads to aberrant STAT3 activation and promotes gliomagenesis. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 8149-8154.	3.3	80
83	DNA amplification method tolerant to sample degradation. Genome Research, 2004, 14, 2357-2366.	2.4	79
84	CLK2 Is an Oncogenic Kinase and Splicing Regulator in Breast Cancer. Cancer Research, 2015, 75, 1516-1526.	0.4	79
85	Hypofractionated Stereotactic Radiotherapy Using Intensity-Modulated Radiotherapy in Patients with One or Two Brain Metastases. Stereotactic and Functional Neurosurgery, 2007, 85, 82-87.	0.8	76
86	Human Mesenchymal glioblastomas are characterized by an increased immune cell presence compared to Proneural and Classical tumors. Oncolmmunology, 2019, 8, e1655360.	2.1	76
87	Glioma oncoprotein Bcl2L12 inhibits the p53 tumor suppressor. Genes and Development, 2010, 24, 2194-2204.	2.7	75
88	A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival. Genes and Development, 2013, 27, 1462-1472.	2.7	74
89	Recruited Cells Can Become Transformed and Overtake PDGF-Induced Murine Gliomas In Vivo during Tumor Progression. PLoS ONE, 2011, 6, e20605.	1.1	72
90	Quiescent human glioblastoma cancer stem cells drive tumor initiation, expansion, and recurrence following chemotherapy. Developmental Cell, 2022, 57, 32-46.e8.	3.1	71

#	Article	IF	CITATIONS
91	Transcriptional diversity of long-term glioblastoma survivors. Neuro-Oncology, 2014, 16, 1186-1195.	0.6	69
92	Candidate Pathways for Promoting Differentiation or Quiescence of Oligodendrocyte Progenitor-like Cells in Glioma. Cancer Research, 2012, 72, 4856-4868.	0.4	68
93	Cell Lineage-Based Stratification for Glioblastoma. Cancer Cell, 2020, 38, 366-379.e8.	7.7	68
94	Common and Distinct Genomic Events in Sporadic Colorectal Cancer and Diverse Cancer Types. Cancer Research, 2007, 67, 10736-10743.	0.4	64
95	Suppression of MicroRNA-9 by Mutant EGFR Signaling Upregulates FOXP1 to Enhance Glioblastoma Tumorigenicity. Cancer Research, 2014, 74, 1429-1439.	0.4	59
96	Ultrasmall Core-Shell Silica Nanoparticles for Precision Drug Delivery in a High-Grade Malignant Brain Tumor Model. Clinical Cancer Research, 2020, 26, 147-158.	3.2	59
97	Isolated translocation of Wernicke's area to the right hemisphere in a 62-year-man with a temporo-parietal glioma. American Journal of Neuroradiology, 2004, 25, 130-3.	1.2	56
98	Balanced-PCR amplification allows unbiased identification of genomic copy changes in minute cell and tissue samples. Nucleic Acids Research, 2004, 32, e76-e76.	6.5	55
99	Discordance between functional magnetic resonance imaging during silent speech tasks and intraoperative speech arrest. Journal of Neurosurgery, 2005, 103, 267-274.	0.9	55
100	Protein Phosphatase 2A Mediates Dormancy of Glioblastoma Multiforme-Derived Tumor Stem-Like Cells during Hypoxia. PLoS ONE, 2012, 7, e30059.	1.1	55
101	Loss of imprinting and marked gene elevation are 2 forms of aberrant IGF2 expression in colorectal cancer. International Journal of Cancer, 2010, 127, 568-577.	2.3	54
102	PRMT6 methylation of RCC1 regulates mitosis, tumorigenicity, and radiation response of glioblastoma stem cells. Molecular Cell, 2021, 81, 1276-1291.e9.	4.5	54
103	The Somatic Genomic Landscape of Glioblastoma. Cell, 2014, 157, 753.	13.5	51
104	TRIM3, a tumor suppressor linked to regulation of p21Waf1/Cip1. Oncogene, 2014, 33, 308-315.	2.6	51
105	INTRAOPERATIVE MAGNETIC RESONANCE IMAGING AT 3-T USING A DUAL INDEPENDENT OPERATING ROOM-MAGNETIC RESONANCE IMAGING SUITE. Neurosurgery, 2008, 63, 412-426.	0.6	50
106	Genetic driver mutations define the expression signature and microenvironmental composition of highâ€grade gliomas. Glia, 2017, 65, 1914-1926.	2.5	50
107	Clinical characterization of human metapneumovirus infection among patients with cancer. Journal of Infection, 2008, 57, 464-471.	1.7	49
108	PRESURGICAL EVALUATION OF LANGUAGE USING FUNCTIONAL MAGNETIC RESONANCE IMAGING IN BRAIN TUMOR PATIENTS WITH PREVIOUS SURGERY. Neurosurgery, 2009, 64, 644-653.	0.6	45

#	Article	IF	CITATIONS
109	Genomic Profiles of Glioma. Current Neurology and Neuroscience Reports, 2011, 11, 291-297.	2.0	39
110	Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas. Journal of Clinical Oncology, 2018, 36, 1702-1709.	0.8	39
111	Mechanisms of stearoyl CoA desaturase inhibitor sensitivity and acquired resistance in cancer. Science Advances, 2021, 7, .	4.7	38
112	MEF Promotes Stemness in the Pathogenesis of Gliomas. Cell Stem Cell, 2012, 11, 836-844.	5.2	37
113	A Principal Components-Based Method for the Detection of Neuronal Activity Maps: Application to Optical Imaging. NeuroImage, 2000, 11, 313-325.	2.1	36
114	Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma. Neuro-Oncology, 2017, 19, 1380-1390.	0.6	35
115	Array comparative genome hybridization for tumor classification and gene discovery in mouse models of malignant melanoma. Cancer Research, 2003, 63, 5352-6.	0.4	34
116	Thalamic Glioblastoma: Clinical Presentation, Management Strategies, and Outcomes. Neurosurgery, 2018, 83, 76-85.	0.6	31
117	EGFR amplification and classical subtype are associated with a poor response to bevacizumab in recurrent glioblastoma. Journal of Neuro-Oncology, 2019, 142, 337-345.	1.4	30
118	Genome-wide methylomic and transcriptomic analyses identify subtype-specific epigenetic signatures commonly dysregulated in glioma stem cells and glioblastoma. Epigenetics, 2018, 13, 432-448.	1.3	29
119	Outcomes and Prognostic Factors in Women With $1\ { m to}\ 3$ Breast Cancer Brain Metastases Treated With Definitive Stereotactic Radiosurgery. International Journal of Radiation Oncology Biology Physics, 2014, 90, 518-525.	0.4	28
120	EGFR and PDGFRA co-expression and heterodimerization in glioblastoma tumor sphere lines. Scientific Reports, 2017, 7, 9043.	1.6	27
121	Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates. Acta Neuropathologica, 2014, 127, 747-759.	3.9	26
122	Ultrasmall dual-modality silica nanoparticle drug conjugates: Design, synthesis, and characterization. Bioorganic and Medicinal Chemistry, 2015, 23, 7119-7130.	1.4	26
123	Genetic and epigenetic landscape of IDH-wildtype glioblastomas with FGFR3-TACC3 fusions. Acta Neuropathologica Communications, 2020, 8, 186.	2.4	26
124	Temporal Lobe Necrosis in Head and Neck Cancer Patients after Proton Therapy to the Skull Base. International Journal of Particle Therapy, 2020, 6, 17-28.	0.9	24
125	Durable 5-year local control for resected brain metastases with early adjuvant SRS: the effect of timing on intended-field control. Neuro-Oncology Practice, 2021, 8, 278-289.	1.0	22
126	Advanced Imaging in Brain Tumor Surgery. Neuroimaging Clinics of North America, 2010, 20, 311-335.	0.5	21

#	Article	IF	CITATIONS
127	Sleeping Beauty Mouse Models Identify Candidate Genes Involved in Gliomagenesis. PLoS ONE, 2014, 9, e113489.	1.1	21
128	Molecular Engineering of Ultrasmall Silica Nanoparticle–Drug Conjugates as Lung Cancer Therapeutics. Clinical Cancer Research, 2020, 26, 5424-5437.	3.2	21
129	Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma. Oncologist, 2020, 25, e1837-e1845.	1.9	21
130	The effect of surgery on radiation necrosis in irradiated brain metastases: extent of resection and long-term clinical and radiographic outcomes. Journal of Neuro-Oncology, 2021, 153, 507-518.	1.4	20
131	Mutant and Wild-Type Isocitrate Dehydrogenase 1 Share Enhancing Mechanisms Involving Distinct Tyrosine Kinase Cascades in Cancer. Cancer Discovery, 2019, 9, 756-777.	7.7	18
132	Development of a gene expression–based prognostic signature for <i>IDH</i> wild-type glioblastoma. Neuro-Oncology, 2020, 22, 1742-1756.	0.6	18
133	Common and Contrasting Genomic Profiles among the Major Human Lung Cancer Subtypes. Cold Spring Harbor Symposia on Quantitative Biology, 2005, 70, 11-24.	2.0	18
134	LY6K promotes glioblastoma tumorigenicity via CAV-1–mediated ERK1/2 signaling enhancement. Neuro-Oncology, 2020, 22, 1315-1326.	0.6	17
135	Clinical outcomes of patients with limited brain metastases treated with hypofractionated (5 \tilde{A} — 6 Gy) conformal radiotherapy. Radiotherapy and Oncology, 2017, 123, 203-208.	0.3	16
136	Salvage resection of recurrent previously irradiated brain metastases: tumor control and radiation necrosis dependency on adjuvant re-irradiation. Journal of Neuro-Oncology, 2021, 155, 277-286.	1.4	16
137	Stereotactic Brain Biopsy With a Low-Field Intraoperative Magnetic Resonance Imager. Operative Neurosurgery, 2011, 68, ons217-ons224.	0.4	13
138	18F-Fluorocholine PET uptake correlates with pathologic evidence of recurrent tumor after stereotactic radiosurgery for brain metastases. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1446-1457.	3.3	13
139	Ultrasmall Nanoparticle Delivery of Doxorubicin Improves Therapeutic Index for High-Grade Glioma. Clinical Cancer Research, 2022, 28, 2938-2952.	3.2	11
140	Defining phenotypic and functional heterogeneity of glioblastoma stem cells by mass cytometry. JCI Insight, 2021, 6, .	2.3	10
141	Cerebrospinal fluid diversion for leptomeningeal metastasis: palliative, procedural and oncologic outcomes. Journal of Neuro-Oncology, 2021, 154, 301-313.	1.4	8
142	Sequencing and curation strategies for identifying candidate glioblastoma treatments. BMC Medical Genomics, 2019, 12, 56.	0.7	7
143	Risk of tract recurrence with stereotactic biopsy of brain metastases: an 18-year cancer center experience. Journal of Neurosurgery, 2022, 136, 1045-1051.	0.9	7
144	Acute inflammatory reactions to hemostatic materials mimicking post-operative intracranial abscess. Interdisciplinary Neurosurgery: Advanced Techniques and Case Management, 2014, 1, 5-7.	0.2	6

#	Article	IF	CITATIONS
145	Prior malignancies in patients harboring glioblastoma: an institutional case-study of 2164 patients. Journal of Neuro-Oncology, 2017, 134, 245-251.	1.4	6
146	The Evolution of 5-Aminolevulinic Acid Fluorescence Visualization: Time for a Headlamp/Loupe Combination. World Neurosurgery, 2022, 159, 136-143.	0.7	6
147	Physics, 2011, 38, 2724-2730.	1.6	5
148	Concurrence of chromosome 6 chromothripsis and glioblastoma metastasis. Journal of Neurosurgery, 2017, 126, 1472-1478.	0.9	4
149	Intracranial metastasis in fibrolamellar hepatocellular carcinoma. Pediatric Blood and Cancer, 2018, 65, e26919.	0.8	4
150	Comprehensive Genome-Wide Profile of Regional Gains and Losses in Multiple Myeloma Using Array-CGH: The 1q21 Amplification and Potential Role of the BCL-9 Gene in Multiple Myeloma Pathogenesis Blood, 2004, 104, 785-785.	0.6	4
151	A brain tumor molecular imaging strategy using a new triple-modality MRI-photoacoustic-Raman nanoparticle. Proceedings of SPIE, $2013, \ldots$	0.8	2
152	FGFR-TACC approaches the first turn in the race for targetable GBM mutations. Neuro-Oncology, 2017, 19, 461-462.	0.6	2
153	Probing the AML Surfaceome for Chimeric Antigen Receptor (CAR) Targets. Blood, 2016, 128, 526-526.	0.6	1
154	Incidence of Prolonged Systemic Steroid Treatment after Surgery for Acoustic Neuroma and Its Implications. Journal of Neurological Surgery, Part B: Skull Base, 2018, 79, 559-568.	0.4	0
155	SURG-03. The effect of surgery on radiation necrosis in irradiated brain metastases: extent of resection and long-term clinical and radiographic outcomes. Neuro-Oncology Advances, 2021, 3, iii23-iii24.	0.4	0
156	Methods for DNA copy number derivations. , 2009, , 25-51.		0
157	Systematic Combinatorial Chimeric Antigen Receptor Therapies to AML. Blood, 2017, 130, 856-856.	0.6	0